Unicycive reports FY 2024 net loss of $37.8M; OLC NDA under FDA review with PDUFA June 28, 2025

Unicycive Therapeutics, Inc.

2025-Q1 EPS reported -$0.05

Net loss attributable to common stockholders $37.8M or $0.56 per share, vs $31.4M ($1.28) in 2023.
Cash and cash equivalents $26.1M as of Dec 31, 2024; company expects to fund operations into 2026.
R&D expenses rose to $20.0M from $12.9M YoY; G&A expenses $12.1M vs $8.5M.
FDA accepted OLC NDA for hyperphosphatemia; PDUFA target action date June 28, 2025.
Commercial planning underway for anticipated OLC launch in late 2025 if approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.